Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry
Yıl: 2023 Cilt: 10 Sayı: 2 Sayfa Aralığı: 513 - 520 Metin Dili: İngilizce DOI: 10.18596/jotcsa.1190202 İndeks Tarihi: 01-06-2023
Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry
Öz: Cytarabine (Cyt) (also known as cytosine arabinoside (ara-C)) used in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL). CYT applied in high doses for treatment can cause renal failure. Monitoring excreted urine drug levels can help kidney failure. For this reason, a method was developed and validated by HPLC-MSMS for urine CYT analysis, which is not included in the literature. In this study, a liquid chromatography (HPLC) with triple quadrupole Mass Spectrometric (MS/MS) method developed for the determination of Cyt from urine for toxicokinetic evaluation. Positive MRM mode selected for the quantification of Cyt. The product and major fragment ion for Cyt 244.0 > 112.0 m/z, for IS 198.0 > 152.0 m/z. The optimal MS parameters for Cyt and IS are as follows Fragmentor 80 V, 70 V, Collision energy, 6, 9 respectively. A novel simple, high-throughput and highly sensitive HPLC-MS/MS method was successfully developed and validated for the determination of Cyt from urine. The developed method has a simple one-step extraction method and a short run time (2.0 minutes) for analysis. The proposed method could be practical and reliable for excretion and toxicokinetic studies and as well as the Therapeutic Drug Monitoring study in humans without an invasive route for Cyt.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Gabriela Chiorean E, Allen Chow W, et al. JOURNAL OF CLINICAL ONCOLOGY A MESSAGE FROM ASCO’S PRESIDENT. 2017 [cited 2023 May 10]; Available from:<URL>
- 2. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer [Internet]. 2018 Jul 1 [cited 2023 May 10];124(13):2785–800. Available from: <URL>
- 3. Lamba JK. Genetic factors influencing cytarabine therapy. [Internet]. 2009 Oct 20 [cited 2023 May 10];10(10):1657–74. Available from: <URL>
- 4. Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet [Internet]. 2002 Sep 13 [cited 2023 May 10];41(10):705–18. Available from: <URL>
- 5. Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. [Internet]. 1999 Sep 30 [cited 2023 May 10];341(14):1051–62. Available from: <URL>
- 6. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine Dose for Acute Myeloid Leukemia. New England Journal of Medicine [Internet]. 2011 Mar 17 [cited 2023 May 10];364(11):1027–36. Available from: <DOI>
- 7. Dotson JL, Jamil MO. Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series. Int J Hematol [Internet]. 2018 Nov 1 [cited 2023 May 10];108(5):554–7. Available from: <URL>
- 8. 1. Mori T, Yamazaki R, Nakazato T, Aisa Y, Enoki S, Arai M, et al. Excretion of cytosine arabinoside in saliva after its administration at high doses. Anti-Cancer Drugs [Internet]. 2006;17(5). Available from: <URL>
- 9. Burk M, Volmer M, Fartash K, Schneider W. Ion-pair liquid chromatography of cytarabine and uracil- arabinoside in human plasma. Arzneimittelforschung [Internet]. 1995 May 1 [cited 2023 May 10];45(5):616–9. Available from: <URL>
- 10. Hsieh Y, Duncan CJG. An ion-pairing liquid chromatography/tandem mass spectrometric method for the determination of cytarabine in mouse plasma. Rapid Communications in Mass Spectrometry [Internet]. 2007 Feb 28 [cited 2023 May 10];21(4):573–8. Available from: <URL>
- 11. Hsieh Y, Duncan CJG, Liu M. A mixed-mode liquid chromatography-tandem mass spectrometric method for the determination of cytarabine in mouse plasma. Journal of Chromatography B. 2007 Jul 1;854(1–2):8– 12. <DOI>.
- 12. HHsieh Y, Duncan CJG, Brisson JM. Porous graphitic carbon chromatography/tandem mass spectrometric determination of cytarabine in mouse plasma. Rapid Communications in Mass Spectrometry [Internet]. 2007 Mar 15 [cited 2023 May 10];21(5):629–34. <DOI>.
- 13. Sun Y, Sun J, Wen B, Shi S, Xu Y, Chen Y, et al. High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma. Journal of Chromatography B. 2008 Jul 1;870(1):121–5. <DOI>.
- 14. Mistiran AF, Dzarr AA, Gan SH. HPLC method development and validation for simultaneous detection of Arabinoside-C and doxorubicin. [Internet]. 2010 Oct 14 [cited 2023 May 10];20(8):472–81. Available from: <URL>
- 15. Hilhorst MJ, Hendriks G, Van Hout MWJ, Sillén H, Van De Merbel NC. HPLC–MS/MS method for the determination of cytarabine in human plasma. [Internet]. 2011 Jul 14 [cited 2023 May 10];3(14):1603–11. Available from: <URL>
- 16. Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012 Oct 1;36(10):1283–9. <DOI>.
- 17. Phillips CL, Lane A, Gerbing RB, Alonzo TA, Wilkey A, Radloff G, et al. Genomic variants of cytarabine sensitivity associated with treatment-related mortality in pediatric AML: A report from the children’s oncology group. Clinical Cancer Research [Internet]. 2020 Jun 15 [cited 2023 May 10];26(12):2891–7. Available from: <URL>
- 18. 2** Committee for Medicinal Products for Human Use (CHMP) Guideline on bioanalytical method validation. 1922 [cited 2023 May 10]; Available from: <URL>
| APA | Daniş İ, Gölcü A, UNAL D (2023). Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. , 513 - 520. 10.18596/jotcsa.1190202 |
| Chicago | Daniş İbrahim,Gölcü Ayşegül,UNAL DURİ SEHVAR Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. (2023): 513 - 520. 10.18596/jotcsa.1190202 |
| MLA | Daniş İbrahim,Gölcü Ayşegül,UNAL DURİ SEHVAR Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. , 2023, ss.513 - 520. 10.18596/jotcsa.1190202 |
| AMA | Daniş İ,Gölcü A,UNAL D Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. . 2023; 513 - 520. 10.18596/jotcsa.1190202 |
| Vancouver | Daniş İ,Gölcü A,UNAL D Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. . 2023; 513 - 520. 10.18596/jotcsa.1190202 |
| IEEE | Daniş İ,Gölcü A,UNAL D "Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry." , ss.513 - 520, 2023. 10.18596/jotcsa.1190202 |
| ISNAD | Daniş, İbrahim vd. "Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry". (2023), 513-520. https://doi.org/10.18596/jotcsa.1190202 |
| APA | Daniş İ, Gölcü A, UNAL D (2023). Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of the Turkish Chemical Society, Section A: Chemistry, 10(2), 513 - 520. 10.18596/jotcsa.1190202 |
| Chicago | Daniş İbrahim,Gölcü Ayşegül,UNAL DURİ SEHVAR Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of the Turkish Chemical Society, Section A: Chemistry 10, no.2 (2023): 513 - 520. 10.18596/jotcsa.1190202 |
| MLA | Daniş İbrahim,Gölcü Ayşegül,UNAL DURİ SEHVAR Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of the Turkish Chemical Society, Section A: Chemistry, vol.10, no.2, 2023, ss.513 - 520. 10.18596/jotcsa.1190202 |
| AMA | Daniş İ,Gölcü A,UNAL D Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of the Turkish Chemical Society, Section A: Chemistry. 2023; 10(2): 513 - 520. 10.18596/jotcsa.1190202 |
| Vancouver | Daniş İ,Gölcü A,UNAL D Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of the Turkish Chemical Society, Section A: Chemistry. 2023; 10(2): 513 - 520. 10.18596/jotcsa.1190202 |
| IEEE | Daniş İ,Gölcü A,UNAL D "Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry." Journal of the Turkish Chemical Society, Section A: Chemistry, 10, ss.513 - 520, 2023. 10.18596/jotcsa.1190202 |
| ISNAD | Daniş, İbrahim vd. "Cytarabine determination from urine for Toxicokinetic and Excretion studies by High- Performance Liquid Chromatography-Tandem Mass Spectrometry". Journal of the Turkish Chemical Society, Section A: Chemistry 10/2 (2023), 513-520. https://doi.org/10.18596/jotcsa.1190202 |
